Belite Bio Reports FDA Review Extension for Tinlarebant
San Diego, California, United States, November 20, 2026 Belite Bio, Inc. has announced that the U.S. Food and Drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
San Diego, California, United States, November 20, 2026 Belite Bio, Inc. has announced that the U.S. Food and Drug...
Durham, North Carolina — October 30, 2026 Atsena Therapeutics announced new preclinical findings for ATSN-301, an investigational dual adeno-associated...
Foster City, California & Wilmington, Delaware, September 25, 2026 Mirum Pharmaceuticals and Incyte have announced a major regulatory milestone...
Rockville, Maryland, U.S., September 24, 2026 REGENXBIO Inc. has presented three-year clinical data for surabgene lomparvovec in patients with...
MALVERN, Pa. — September 25, 2026 Ocugen Inc. announced that its investigational modifier gene therapy OCU400 has received provisional...
RAHWAY, N.J. — September 24, 2026 Merck announced topline results from the pivotal Phase 2b/3 BRUNELLO study evaluating remigromig...
Basel, Switzerland, September 21, 2026 Roche has announced that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL) for...
LONDON and CAMBRIDGE, Mass September 21, 2026 — Beacon Therapeutics announced positive topline results from the pivotal VISTA trial...
BEDFORD, Mass. — September 15, 2026 Ocular Therapeutix, Inc. announced the successful completion of its Pre-New Drug Application (Pre-NDA)...
Dallas, Texas, USA, September 9, 2026 Nanoscope Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has...
